In addition, based on preclinical studies suggesting that activation mutations or amplification of the FGFR pathway cause acquired resistance to CDK4/6 inhibitors, the FGFR tyrosine kinase inhibitor lucitanib has been clinically tested in patients with advanced breast cancer [14]. The gene discussed is CDK4; the disease is breast cancer.